Prof Shankar Siva
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
588 Scholarly works
9 Projects
HIGHLIGHTS
2026
Journal article
Neoadjuvant therapies for clear cell renal cell carcinoma: review of current evidence and future applications
DOI: 10.1007/s00345-026-06603-x2026
Journal article
Deep learning and radiomics models in patients with advanced non-small cell lung cancer treated with immunotherapy combined with stereotactic radiotherapy
DOI: 10.1038/s41598-026-53520-52023
Research grants (ARC, NHMRC, MRFF)
Reducing the Impact of Radiation on the Heart for Cancer and Cardiac Disease Patients
2020
Research grants (other domestic)
Stereotactic Ablative Body Radiotherapy (Sabr) as a Catalyst to Improve Outcomes From Immunotherapy
2018
Journal article
Cold kit for prostate-Specific membrane antigen (PSMA) PET imaging: Phase 1 study of 68Ga-Tris (Hydroxypyridinone)-PSMA PET/CT in patients with prostate cancer
DOI: 10.2967/jnumed.117.1995542018
Research Grant
Stereotactic Ablative Radiotherapy (Sabr) as a New Precision Treatment Option in Kidney Cancer
2017
Conference Proceedings
Cold Kit PSMA Imaging: First In-Man Study of 68Ga-THP-PSMA PET/CT in Patients with Prostate Cancer
RECENT SCHOLARLY WORKS
2026
Journal article
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma
DOI: 10.1038/s41467-026-74255-x2026
Journal article
Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial
DOI: 10.1038/s41467-026-75660-y2026
Journal article
Management of De Novo miN1 Prostate Cancer in the PSMA-PET Era
DOI: 10.1002/pros.702312026
Journal article
Clinical outcomes of stereotactic body radiotherapy in oligometastatic disease: a national real-world cohort study.
DOI: 10.1007/s12094-026-04557-52026
Journal article
Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician's choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II)
DOI: 10.1136/bmjopen-2026-1198112026
Journal article
Inconsistent definitions of local control for stereotactic body radiation therapy for early-stage lung cancer – A systematic review
DOI: 10.1016/j.radonc.2026.1116952026
Journal article
Pre-clinical data interpretation requires clinical context
DOI: 10.1038/s41586-026-10774-32026
Journal article
A Response to the Letter to the Editor: Radiotherapy to the Primary, With or Without Total Metastatic Ablation
DOI: 10.1016/j.jtho.2026.103926